Free Trial
NASDAQ:ELAB

Elevai Labs (ELAB) Stock Price, News & Analysis

Elevai Labs logo
$4.85 -0.03 (-0.61%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$4.84 -0.01 (-0.12%)
As of 03/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Elevai Labs Stock (NASDAQ:ELAB)

Key Stats

Today's Range
$4.71
$5.07
50-Day Range
$3.92
$21.70
52-Week Range
$3.88
$1,064.00
Volume
23,406 shs
Average Volume
136,203 shs
Market Capitalization
$2.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Remove Ads

Elevai Labs Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

ELAB MarketRank™: 

Elevai Labs scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Elevai Labs.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevai Labs is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevai Labs is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elevai Labs has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Elevai Labs' valuation and earnings.
  • Percentage of Shares Shorted

    0.74% of the float of Elevai Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevai Labs has recently increased by 14.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elevai Labs does not currently pay a dividend.

  • Dividend Growth

    Elevai Labs does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.74% of the float of Elevai Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevai Labs has recently increased by 14.95%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Elevai Labs has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Multi-Sector Conglomerates companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Elevai Labs this week, compared to 1 article on an average week.
  • MarketBeat Follows

    6 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevai Labs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.60% of the stock of Elevai Labs is held by insiders.

  • Percentage Held by Institutions

    Only 22.22% of the stock of Elevai Labs is held by institutions.

  • Read more about Elevai Labs' insider trading history.
Receive ELAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter.

ELAB Stock News Headlines

Musk’s real agenda in D.C.
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
PMGC Holdings Inc. Common Stock (ELAB)
See More Headlines

ELAB Stock Analysis - Frequently Asked Questions

Elevai Labs' stock was trading at $16.03 on January 1st, 2025. Since then, ELAB shares have decreased by 69.7% and is now trading at $4.85.
View the best growth stocks for 2025 here
.

Shares of Elevai Labs reverse split on Monday, March 10th 2025. The 1-7 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, March 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Elevai Labs (ELAB) raised $6 million in an IPO on Tuesday, November 21st 2023. The company issued 1,500,000 shares at $4.00 per share. Univest Securities served as the underwriter for the IPO.

Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII).

Company Calendar

Today
3/31/2025
Next Earnings (Estimated)
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELAB
Previous Symbol
NASDAQ:ELAB
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,300,000.00
Net Margins
-223.41%
Pretax Margin
-223.37%

Debt

Sales & Book Value

Annual Sales
$2.45 million
Price / Cash Flow
N/A
Book Value
$44.17 per share
Price / Book
0.11

Miscellaneous

Free Float
3,033,000
Market Cap
$2.80 million
Optionable
N/A
Beta
-2.95
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ELAB) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners